Patient characteristics and type of treatment of the entire cohort (N = 398)
| Characteristic . | Data . |
|---|---|
| Males/females | 294 (74)/104 (26) |
| ECOG score 0-1 | 207 (65) |
| Age, median (range), y | 67 (18-96) |
| Localization | |
| Skin | 353 (89) |
| BM | 243 (62) |
| Peripheral blood | 36 (15) |
| Lymph nodes | 152 (39) |
| Forms | |
| Cutaneous isolated | 121 (30) |
| Disseminated with cutaneous localization | 200 (50) |
| Disseminated with cutaneous and extranodal localization | 26 (7) |
| Disseminated noncutaneous | 43 (11) |
| Disseminated noncutaneous with extranodal localization | 8 (2) |
| Karyotype (available for 96 patients) | |
| Normal | 44 (46) |
| Abnormal | 52 (54) |
| Complex (CK+) | 32 (33) |
| Monosomic (MK+) | 16 (17) |
| MK+MC+ ≥ 5 | 6 (6) |
| Type of treatment | 394 (100) |
| Chemotherapy without consolidation | 222 (56.3) |
| NHL-like | 129 (32.8) |
| ALL-like* | 57 (14.4) |
| AML-like | 36 (9.1) |
| Chemotherapy + allo-HSCT | 61 (15.5) |
| ALL-like + allo-HSCT | 33 (8.4) |
| AML-like + allo-HSCT | 16 (4.1) |
| NHL-like + allo-HSCT | 12 (3.0) |
| Chemotherapy + auto-HSCT | 16 (4.1) |
| ALL-like + auto-HSCT | 6 (1.5) |
| AML-like + auto-HSCT | 1 (0.3) |
| NHL-like + auto-HSCT | 9 (2.3) |
| Radiotherapy | 27 (6.9) |
| New drugs (SL401, bortezomib, azacitidine) | 6 (1.5) |
| Palliative | 62 (15.7) |
| Characteristic . | Data . |
|---|---|
| Males/females | 294 (74)/104 (26) |
| ECOG score 0-1 | 207 (65) |
| Age, median (range), y | 67 (18-96) |
| Localization | |
| Skin | 353 (89) |
| BM | 243 (62) |
| Peripheral blood | 36 (15) |
| Lymph nodes | 152 (39) |
| Forms | |
| Cutaneous isolated | 121 (30) |
| Disseminated with cutaneous localization | 200 (50) |
| Disseminated with cutaneous and extranodal localization | 26 (7) |
| Disseminated noncutaneous | 43 (11) |
| Disseminated noncutaneous with extranodal localization | 8 (2) |
| Karyotype (available for 96 patients) | |
| Normal | 44 (46) |
| Abnormal | 52 (54) |
| Complex (CK+) | 32 (33) |
| Monosomic (MK+) | 16 (17) |
| MK+MC+ ≥ 5 | 6 (6) |
| Type of treatment | 394 (100) |
| Chemotherapy without consolidation | 222 (56.3) |
| NHL-like | 129 (32.8) |
| ALL-like* | 57 (14.4) |
| AML-like | 36 (9.1) |
| Chemotherapy + allo-HSCT | 61 (15.5) |
| ALL-like + allo-HSCT | 33 (8.4) |
| AML-like + allo-HSCT | 16 (4.1) |
| NHL-like + allo-HSCT | 12 (3.0) |
| Chemotherapy + auto-HSCT | 16 (4.1) |
| ALL-like + auto-HSCT | 6 (1.5) |
| AML-like + auto-HSCT | 1 (0.3) |
| NHL-like + auto-HSCT | 9 (2.3) |
| Radiotherapy | 27 (6.9) |
| New drugs (SL401, bortezomib, azacitidine) | 6 (1.5) |
| Palliative | 62 (15.7) |
Unless otherwise noted, data are n (%).
Including Hyper-CVAD regimen and Aspa-MTX.